Search

Author/Creator Holland, Jaymes

1. Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Cabozantinib. (23rd March 2016)

Authors:
Nguyen, Linh; Holland, Jaymes; Ramies, David; Mamelok, Richard; Benrimoh, Natacha; Ciric, Sabrina; Marbury, Thomas; Preston, Richard A.; Heuman, Douglas M.; Gavis, Edith; Lacy, Steven
Journal:
Journal of clinical pharmacology
Issue:
Volume 56:Number 9(2016)
Page Start:
1130
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Evaluation of the effect of food and gastric pH on the single‐dose pharmacokinetics of cabozantinib in healthy adult subjects. (26th June 2015)

Authors:
Nguyen, Linh; Holland, Jaymes; Mamelok, Richard; Laberge, Marie‐Kristine; Grenier, Julie; Swearingen, Dennis; Armas, Danielle; Lacy, Steven
Journal:
Journal of clinical pharmacology
Issue:
Volume 55:Number 11(2015:Nov.)
Page Start:
1293
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK. (2nd June 2015)

Authors:
Nguyen, Linh; Holland, Jaymes; Miles, Dale; Engel, Caroline; Benrimoh, Natacha; O'Reilly, Terry; Lacy, Steven
Journal:
Journal of clinical pharmacology
Issue:
Volume 55:Number 9(2015:Sep.)
Page Start:
1012
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy. Issue 2 (14th August 2017)

Authors:
Wen, Patrick Y; Drappatz, Jan; de Groot, John; Prados, Michael D; Reardon, David A; Schiff, David; Chamberlain, Marc; Mikkelsen, Tom; Desjardins, Annick; Holland, Jaymes; Ping, Jerry; Weitzman, Ron; Cloughesy, Timothy F
Journal:
Neuro-oncology
Issue:
Volume 20:Issue 2(2018)
Page Start:
249
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy. Issue 2 (3rd October 2017)

Authors:
Cloughesy, Timothy F; Drappatz, Jan; de Groot, John; Prados, Michael D; Reardon, David A; Schiff, David; Chamberlain, Marc; Mikkelsen, Tom; Desjardins, Annick; Ping, Jerry; Holland, Jaymes; Weitzman, Ron; Wen, Patrick Y
Journal:
Neuro-oncology
Issue:
Volume 20:Issue 2(2018)
Page Start:
259
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma. Issue 10 (5th April 2018)

Authors:
Ellingson, Benjamin M; Aftab, Dana T; Schwab, Gisela M; Hessel, Colin; Harris, Robert J; Woodworth, Davis C; Leu, Kevin; Chakhoyan, Ararat; Raymond, Catalina; Drappatz, Jan; de Groot, John; Prados, Michael D; Reardon, David A; Schiff, David; Chamberlain, Marc; Mikkelsen, Tom; Desjardins, Annick; ...
Journal:
Neuro-oncology
Issue:
Volume 20:Issue 10(2018)
Page Start:
1411
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗